Use of Sitagliptin with Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes

Lisa J. Underland, Jeniece Trast Ilkowitz, Ranjitha Katikaneni, Amy Dowd, Rubina A. Heptulla

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Postprandial hyperglycemia poses a challenge to closed-loop systems. Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin, reduce postprandial glucose concentrations in patients with type 2 diabetes. The objective of this study was to assess sitagliptin's role in type 1 diabetes (T1DM) as an adjunct therapy in reducing postprandial blood glucose with an insulin-only closed-loop system. Methods: This was a randomized, double-blinded, placebo controlled, crossover design trial. The participants were18-35 years old, had T1DM, and an HbA1c of ≤ 8.5%. A dose determination study included eight subjects with T1DM. There were three study visits. Four hours after receiving study drug (placebo, sitagliptin 50 mg, sitagliptin 100 mg), subjects underwent a mixed meal tolerance test with assessment of hormone concentrations. In a second study, 15 subjects underwent two visits receiving either placebo or 100 mg of sitagliptin plus an insulin only closed-loop system for 25 hours with timed meals. Blood glucose and other hormone concentrations were analyzed using repeated measures ANOVA. Results: For the dose determination study, sitagliptin 100 mg resulted in reduced postprandial blood glucose (P =.006). For the closed-loop study, glucose concentrations were lower in the treatment group, most prominently during the first two study meals (P =.03). There was no difference in glucagon concentrations, but insulin concentrations and insulin delivery were lower in the treatment group. Conclusions: Sitagliptin may be considered as an adjunct therapy in a closed-loop setting. Larger studies are needed to determine the role of oral agents like sitagliptin to lower postprandial hyperglycemia with closed loop.

Original languageEnglish (US)
Pages (from-to)602-610
Number of pages9
JournalJournal of diabetes science and technology
Volume11
Issue number3
DOIs
StatePublished - May 1 2017

Fingerprint

Medical problems
Type 1 Diabetes Mellitus
Insulin
Glucose
Blood Glucose
Blood
Technology
Closed loop systems
Hormones
Meals
Placebos
Hyperglycemia
Cross-Over Studies
Analysis of variance (ANOVA)
Dipeptidyl-Peptidase IV Inhibitors
Sitagliptin Phosphate
Therapeutics
Glucagon
Type 2 Diabetes Mellitus
Analysis of Variance

Keywords

  • artificial pancreas
  • closed loop
  • sitagliptin
  • type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Cite this

Use of Sitagliptin with Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes. / Underland, Lisa J.; Ilkowitz, Jeniece Trast; Katikaneni, Ranjitha; Dowd, Amy; Heptulla, Rubina A.

In: Journal of diabetes science and technology, Vol. 11, No. 3, 01.05.2017, p. 602-610.

Research output: Contribution to journalArticle

Underland, Lisa J. ; Ilkowitz, Jeniece Trast ; Katikaneni, Ranjitha ; Dowd, Amy ; Heptulla, Rubina A. / Use of Sitagliptin with Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes. In: Journal of diabetes science and technology. 2017 ; Vol. 11, No. 3. pp. 602-610.
@article{7a8ec168fce14f0caa7ea44b8a18eb0c,
title = "Use of Sitagliptin with Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes",
abstract = "Background: Postprandial hyperglycemia poses a challenge to closed-loop systems. Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin, reduce postprandial glucose concentrations in patients with type 2 diabetes. The objective of this study was to assess sitagliptin's role in type 1 diabetes (T1DM) as an adjunct therapy in reducing postprandial blood glucose with an insulin-only closed-loop system. Methods: This was a randomized, double-blinded, placebo controlled, crossover design trial. The participants were18-35 years old, had T1DM, and an HbA1c of ≤ 8.5{\%}. A dose determination study included eight subjects with T1DM. There were three study visits. Four hours after receiving study drug (placebo, sitagliptin 50 mg, sitagliptin 100 mg), subjects underwent a mixed meal tolerance test with assessment of hormone concentrations. In a second study, 15 subjects underwent two visits receiving either placebo or 100 mg of sitagliptin plus an insulin only closed-loop system for 25 hours with timed meals. Blood glucose and other hormone concentrations were analyzed using repeated measures ANOVA. Results: For the dose determination study, sitagliptin 100 mg resulted in reduced postprandial blood glucose (P =.006). For the closed-loop study, glucose concentrations were lower in the treatment group, most prominently during the first two study meals (P =.03). There was no difference in glucagon concentrations, but insulin concentrations and insulin delivery were lower in the treatment group. Conclusions: Sitagliptin may be considered as an adjunct therapy in a closed-loop setting. Larger studies are needed to determine the role of oral agents like sitagliptin to lower postprandial hyperglycemia with closed loop.",
keywords = "artificial pancreas, closed loop, sitagliptin, type 1 diabetes",
author = "Underland, {Lisa J.} and Ilkowitz, {Jeniece Trast} and Ranjitha Katikaneni and Amy Dowd and Heptulla, {Rubina A.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1177/1932296817699847",
language = "English (US)",
volume = "11",
pages = "602--610",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "3",

}

TY - JOUR

T1 - Use of Sitagliptin with Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes

AU - Underland, Lisa J.

AU - Ilkowitz, Jeniece Trast

AU - Katikaneni, Ranjitha

AU - Dowd, Amy

AU - Heptulla, Rubina A.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Postprandial hyperglycemia poses a challenge to closed-loop systems. Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin, reduce postprandial glucose concentrations in patients with type 2 diabetes. The objective of this study was to assess sitagliptin's role in type 1 diabetes (T1DM) as an adjunct therapy in reducing postprandial blood glucose with an insulin-only closed-loop system. Methods: This was a randomized, double-blinded, placebo controlled, crossover design trial. The participants were18-35 years old, had T1DM, and an HbA1c of ≤ 8.5%. A dose determination study included eight subjects with T1DM. There were three study visits. Four hours after receiving study drug (placebo, sitagliptin 50 mg, sitagliptin 100 mg), subjects underwent a mixed meal tolerance test with assessment of hormone concentrations. In a second study, 15 subjects underwent two visits receiving either placebo or 100 mg of sitagliptin plus an insulin only closed-loop system for 25 hours with timed meals. Blood glucose and other hormone concentrations were analyzed using repeated measures ANOVA. Results: For the dose determination study, sitagliptin 100 mg resulted in reduced postprandial blood glucose (P =.006). For the closed-loop study, glucose concentrations were lower in the treatment group, most prominently during the first two study meals (P =.03). There was no difference in glucagon concentrations, but insulin concentrations and insulin delivery were lower in the treatment group. Conclusions: Sitagliptin may be considered as an adjunct therapy in a closed-loop setting. Larger studies are needed to determine the role of oral agents like sitagliptin to lower postprandial hyperglycemia with closed loop.

AB - Background: Postprandial hyperglycemia poses a challenge to closed-loop systems. Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin, reduce postprandial glucose concentrations in patients with type 2 diabetes. The objective of this study was to assess sitagliptin's role in type 1 diabetes (T1DM) as an adjunct therapy in reducing postprandial blood glucose with an insulin-only closed-loop system. Methods: This was a randomized, double-blinded, placebo controlled, crossover design trial. The participants were18-35 years old, had T1DM, and an HbA1c of ≤ 8.5%. A dose determination study included eight subjects with T1DM. There were three study visits. Four hours after receiving study drug (placebo, sitagliptin 50 mg, sitagliptin 100 mg), subjects underwent a mixed meal tolerance test with assessment of hormone concentrations. In a second study, 15 subjects underwent two visits receiving either placebo or 100 mg of sitagliptin plus an insulin only closed-loop system for 25 hours with timed meals. Blood glucose and other hormone concentrations were analyzed using repeated measures ANOVA. Results: For the dose determination study, sitagliptin 100 mg resulted in reduced postprandial blood glucose (P =.006). For the closed-loop study, glucose concentrations were lower in the treatment group, most prominently during the first two study meals (P =.03). There was no difference in glucagon concentrations, but insulin concentrations and insulin delivery were lower in the treatment group. Conclusions: Sitagliptin may be considered as an adjunct therapy in a closed-loop setting. Larger studies are needed to determine the role of oral agents like sitagliptin to lower postprandial hyperglycemia with closed loop.

KW - artificial pancreas

KW - closed loop

KW - sitagliptin

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85018995962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018995962&partnerID=8YFLogxK

U2 - 10.1177/1932296817699847

DO - 10.1177/1932296817699847

M3 - Article

VL - 11

SP - 602

EP - 610

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 3

ER -